Patents by Inventor Masatoshi Kakushima

Masatoshi Kakushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of ??integrin mediated cell adhesion
    Patent number: 7375128
    Abstract: The present invention relates to a compound of formula (I): wherein R is hydrogen atom, hydroxyl group or carbamoyl group, and n is 1 or 2, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: May 20, 2008
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Ila Sircar, Marshall Morningstar, Masatoshi Kakushima, Hidefumi Kaji, Takayuki Kawaguchi, Toshiyuki Kume
  • Inhibitors of alpha l beta 2 integrin mediated cell adhesion
    Publication number: 20050171174
    Abstract: The present invention relates to a compound of formula (I): wherein R is hydrogen atom, hydroxyl group or carbamoyl group, and n is 1 or 2, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 6, 2003
    Publication date: August 4, 2005
    Inventors: IIa Sircar, Marshall Morningstar, Masatoshi Kakushima
  • Production of pradimicin antibiotics
    Patent number: 5374552
    Abstract: The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: December 20, 1994
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Yoichiro Saitoh, Seikichi Kobaru
  • Production of pradimicin antibiotics
    Patent number: 5194371
    Abstract: The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).
    Type: Grant
    Filed: July 31, 1991
    Date of Patent: March 16, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Kyoichiro Saitoh, Seikichi Kobaru
  • Method for treating fungal infections with serine analogs of BU-3608 antibiotics
    Patent number: 5183808
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: February 19, 1992
    Date of Patent: February 2, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Actinomadura hibisca microorganism useful for preparing serine analogs of BU-3608 antibiotics
    Patent number: 5114857
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: May 14, 1991
    Date of Patent: May 19, 1992
    Assignee: Bristol-Myers Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Serine analogs of BU-3608 antibiotics
    Patent number: 5061624
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: October 29, 1991
    Assignee: Bristol-Myers Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Leukotriene antagonists
    Patent number: 5017583
    Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
    Type: Grant
    Filed: February 23, 1988
    Date of Patent: May 21, 1991
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Joshua Rokach, Haydn R. Williams, Masatoshi Kakushima, Yvan Guindon
  • Leukotriene antagonists
    Patent number: 4983628
    Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reaction substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: January 3, 1989
    Date of Patent: January 8, 1991
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Frenette, Joshua Rokach, Masatoshi Kakushima, Robert N. Young
  • Serine analogs of BU-3608 antibiotics
    Patent number: 4973673
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: November 10, 1988
    Date of Patent: November 27, 1990
    Assignee: Bristol-Myers Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • BU-3608 derivatives
    Patent number: 4960755
    Abstract: Disclosed herein are N-alkyl derivatives of antibiotics BU-3608, BU-3608 B, C, D and E as well as the corresponding desxylosyl compounds. These novel compounds are useful as antifungal agents.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: October 2, 1990
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Masatoshi Kakushima, Masataka Konishi, Toshikazu Oki
  • Leukotriene antagonists
    Patent number: 4918092
    Abstract: Compounds having the formula I: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic and anti-inflammatory agents.
    Type: Grant
    Filed: January 15, 1988
    Date of Patent: April 17, 1990
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Frenette, Robert N. Young, Masatoshi Kakushima
  • Stereoselective synthesis of leukotriene antagonists
    Patent number: 4857659
    Abstract: The present invention relates to a stereo-selective synthesis of leukotriene antagonists. More particularly, this invention relates to the stereo-selective synthesis of (.beta.S,.gamma.R) and (.beta.R,.gamma.S)-4-((3-(4-acetyl-3-hydroxy-2-propyl(phenoxy)propyl)-thio -.gamma.-hydroxy-.beta.-methylbenzenebutanoic acid, and related compounds. These compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular, disorders, inflammation and pain in mammals, especially humans. The compounds are also useful for inducing cytoprotection in mammals, especially humans.
    Type: Grant
    Filed: April 15, 1987
    Date of Patent: August 15, 1989
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Frenette, Jacques-Yves Gauthier, Robert N. Young, Robert Zamboni, Masatoshi Kakushima, Thomas R. Verhoeven
  • Leukotriene antagonists
    Patent number: 4683325
    Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: October 17, 1984
    Date of Patent: July 28, 1987
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Frenette, Joshua Rokach, Masatoshi Kakushima, Robert N. Young
  • 4-oxo-benzopyran carboxylic acids
    Patent number: 4609744
    Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
    Type: Grant
    Filed: March 19, 1984
    Date of Patent: September 2, 1986
    Assignee: Merck Frosst Canada Inc.
    Inventors: Robert N. Young, Joshua Rokach, Haydn R. Williams, Masatoshi Kakushima, Yvan Guindon